562 related articles for article (PubMed ID: 25935581)
1. Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
Charytan DM; Lewis EF; Desai AS; Weinrauch LA; Ivanovich P; Toto RD; Claggett B; Liu J; Hartley LH; Finn P; Singh AK; Levey AS; Pfeffer MA; McMurray JJ; Solomon SD
Am J Kidney Dis; 2015 Sep; 66(3):429-40. PubMed ID: 25935581
[TBL] [Abstract][Full Text] [Related]
2. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
[TBL] [Abstract][Full Text] [Related]
3. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill J; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R; Uno H;
Am J Kidney Dis; 2009 Jul; 54(1):59-69. PubMed ID: 19501439
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
Mc Causland FR; Claggett B; Burdmann EA; Chertow GM; Cooper ME; Eckardt KU; Ivanovich P; Levey AS; Lewis EF; McGill JB; McMurray JJV; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto RD; Pfeffer MA
Am J Kidney Dis; 2019 Mar; 73(3):309-315. PubMed ID: 30578152
[TBL] [Abstract][Full Text] [Related]
5. Association of serum chloride level with mortality and cardiovascular events in chronic kidney disease: the CKD-ROUTE study.
Mandai S; Kanda E; Iimori S; Naito S; Noda Y; Kikuchi H; Akazawa M; Oi K; Toda T; Sohara E; Okado T; Sasaki S; Rai T; Uchida S
Clin Exp Nephrol; 2017 Feb; 21(1):104-111. PubMed ID: 27039905
[TBL] [Abstract][Full Text] [Related]
6. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).
Imai E; Maruyama S; Nangaku M; Hirakata H; Hayashi T; Narita I; Kono H; Nakatani E; Morita S; Tsubakihara Y; Akizawa T
Clin Exp Nephrol; 2016 Feb; 20(1):71-6. PubMed ID: 26081567
[TBL] [Abstract][Full Text] [Related]
7. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
[TBL] [Abstract][Full Text] [Related]
8. Risk of Rapid Kidney Function Decline, All-Cause Mortality, and Major Cardiovascular Events in Nonalbuminuric Chronic Kidney Disease in Type 2 Diabetes.
Buyadaa O; Magliano DJ; Salim A; Koye DN; Shaw JE
Diabetes Care; 2020 Jan; 43(1):122-129. PubMed ID: 31796570
[TBL] [Abstract][Full Text] [Related]
9. C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
Mc Causland FR; Claggett B; Burdmann EA; Eckardt KU; Kewalramani R; Levey AS; McMurray JJ; Parfrey P; Remuzzi G; Singh AK; Solomon SD; Toto RD; Pfeffer MA
Am J Kidney Dis; 2016 Dec; 68(6):873-881. PubMed ID: 27646425
[TBL] [Abstract][Full Text] [Related]
10. Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study.
Penno G; Solini A; Bonora E; Orsi E; Fondelli C; Zerbini G; Trevisan R; Vedovato M; Cavalot F; Laviola L; Nicolucci A; Pugliese G;
Acta Diabetol; 2018 Jun; 55(6):603-612. PubMed ID: 29574497
[TBL] [Abstract][Full Text] [Related]
11. Low serum bilirubin level predicts the development of chronic kidney disease in patients with type 2 diabetes mellitus.
Ahn KH; Kim SS; Kim WJ; Kim JH; Nam YJ; Park SB; Jeon YK; Kim BH; Kim IJ; Kim YK
Korean J Intern Med; 2017 Sep; 32(5):875-882. PubMed ID: 28560862
[TBL] [Abstract][Full Text] [Related]
12. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Feyzi JM; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill JB; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R;
N Engl J Med; 2009 Nov; 361(21):2019-32. PubMed ID: 19880844
[TBL] [Abstract][Full Text] [Related]
13. High-normal serum uric acid predicts the development of chronic kidney disease in patients with type 2 diabetes mellitus and preserved kidney function.
Kim WJ; Kim SS; Bae MJ; Yi YS; Jeon YK; Kim BH; Song SH; Kim IJ; Kim YK
J Diabetes Complications; 2014; 28(2):130-4. PubMed ID: 24438886
[TBL] [Abstract][Full Text] [Related]
14. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
Charytan DM; Solomon SD; Ivanovich P; Remuzzi G; Cooper ME; McGill JB; Parving HH; Parfrey P; Singh AK; Burdmann EA; Levey AS; Eckardt KU; McMurray JJV; Weinrauch LA; Liu J; Claggett B; Lewis EF; Pfeffer MA
Diabetes Obes Metab; 2019 May; 21(5):1199-1208. PubMed ID: 30672083
[TBL] [Abstract][Full Text] [Related]
15. The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease.
Sonmez A; Yilmaz MI; Saglam M; Unal HU; Gok M; Cetinkaya H; Karaman M; Haymana C; Eyileten T; Oguz Y; Vural A; Rizzo M; Toth PP
Lipids Health Dis; 2015 Apr; 14():29. PubMed ID: 25885289
[TBL] [Abstract][Full Text] [Related]
16. Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial.
Villar E; Lièvre M; Kessler M; Lemaître V; Alamartine E; Rodier M; François M; Zaoui P; Moranne O; Choukroun G; Guerraoui A; Jolivot A; Janin G; Branger B; Heng AE; Boudray C; Bissery A; Rabilloud M; Pouteil-Noble C
J Diabetes Complications; 2011; 25(4):237-43. PubMed ID: 21601481
[TBL] [Abstract][Full Text] [Related]
17. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT).
McMurray JJ; Uno H; Jarolim P; Desai AS; de Zeeuw D; Eckardt KU; Ivanovich P; Levey AS; Lewis EF; McGill JB; Parfrey P; Parving HH; Toto RM; Solomon SD; Pfeffer MA
Am Heart J; 2011 Oct; 162(4):748-755.e3. PubMed ID: 21982669
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of stage 1-5 chronic kidney disease in Mainland China.
Lai X; Zhang AH; Chen SY; He L; Su CY; Fan MH; Wang T
Ren Fail; 2014 May; 36(4):520-5. PubMed ID: 24456114
[TBL] [Abstract][Full Text] [Related]
19. Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT).
Theilade S; Claggett B; Hansen TW; Skali H; Lewis EF; Solomon SD; Parving HH; Pfeffer M; McMurray JJ; Rossing P;
J Hum Hypertens; 2016 Jan; 30(1):46-52. PubMed ID: 25810068
[TBL] [Abstract][Full Text] [Related]
20. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.
Perkovic V; Toto R; Cooper ME; Mann JFE; Rosenstock J; McGuire DK; Kahn SE; Marx N; Alexander JH; Zinman B; Pfarr E; Schnaidt S; Meinicke T; von Eynatten M; George JT; Johansen OE; Wanner C;
Diabetes Care; 2020 Aug; 43(8):1803-1812. PubMed ID: 32444457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
